The 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) will be held on May 30th through June 3rd, 2008 in Chicago, Illinois. Under a new policy, ASCO publicly released clinical trial brief abstracts two weeks before the start of its 2008 Annual Meeting on May 30th, where full results will be presented before thousands of cancer doctors. The new ASCO policy was intended to avoid stock trading on non-public information that was believed to have occurred under a prior policy in which ASCO mailed out abstracts under embargo weeks before its annual meeting.
I have provided hyperlinks below to a variety of cancer topics that may be of interest to ovarian cancer survivors. Please note that with the exception of the first “ovarian cancer” category listed below, the remaining categories will contain abstracts that address various types of cancer. H*O*P*E*™ will provide one or more posts that address ovarian cancer abstract highlights after the completion of the 2008 ASCO Annual Meeting on June 3rd.
Developmental Therapeutics: Cytotoxic Chemotherapy:
Developmental Therapeutics: Immunotherapy:
Developmental Therapeutics: Molecular Therapeutics:
Antiangiogenic or Antimetastatic Agents
Cell Cycle Inhibitors
Gene Therapy/Antisense Strategies
Other Novel Agents
Tyrosine Kinase Inhibitors
Tumor Biology and Human Genetics:
Epidemiology / Molecular Epidemiology
Molecular Diagnostics and Staging
Other: Tumor Biology and Human Genetics
Tumor and Cell Biology
Health Services Research: